KoBioLabs, Inc. Q3 revenue KRW 20.4 billion, loss of KRW 3.2 billion from main business
AI summary · Not investment advice
Gobiolab sold KRW 20.4 billion worth in Q3 and lost KRW 3.2 billion from its main business, versus a KRW 0.4 billion loss a year earlier.
Operating profit · 3 months
KRW -3.2 billion
Key facts
- Revenue (3 months)
- KRW 20.4 billion
- Net income (3 months)
- KRW -2.5 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 19.3 billion
- Revenue (year to date)
- KRW 61.5 billion
- Operating profit (prior-year 3 months)
- KRW -422.6 millionOperating loss
- Operating profit (year to date)
- KRW -7.8 billionOperating loss
- Net income (prior-year 3 months)
- KRW 855.8 millionNet income in the prior-year same period
- Net income (year to date)
- KRW -6.6 billionQuarterly net loss
Commentary
AI commentary · Not investment advice
What happened
Gobiolab filed its quarterly report with consolidated results for the third quarter of this year. Sales for the three months were KRW 20.4 billion. That is 6.2% more than the same period a year earlier. It is 6.2% less than the previous quarter. Cumulative sales for the year so far were KRW 61.5 billion.
In the company's terms
Operating profit (profit from the core business) for the three months was a loss of KRW 3.2 billion. A year earlier, the same period had an operating loss of KRW 0.4 billion. The cumulative operating loss for the year so far was KRW 7.8 billion.
What changes for shareholders
Net income (the final profit after taxes and other items) for the three months was a loss of KRW 2.5 billion. A year earlier, the same period had a net profit of KRW 0.9 billion, so it turned to a loss. The cumulative net loss for the year so far was KRW 6.6 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
K